Planet 13 Holdings (PLNH) Income from Continuing Operations (2021 - 2026)
Planet 13 Holdings (PLNH) posted quarterly Income from Continuing Operations of 8095802.0 for Q1 2026, down 180.63% year-over-year from 10041119.36 in Q1 2025, and down 215.53% quarter-over-quarter from 7007274.0 in Q4 2025.
Planet 13 Holdings (PLNH) Income from Continuing Operations (2021 - 2026) Analysis & Trends
Planet 13 Holdings (PLNH) has reported Income from Continuing Operations for 6 consecutive years, with 8095802.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 180.63% year-over-year to 8095802.0; the TTM figure through Mar 2026 stood at 58345623.0 (down 80.37% YoY), while the FY2025 annual figure was 52296988.0, down 46.87% from the prior year.
- Income from Continuing Operations fell to 8095802.0 in Q1 2026 per PLNH's latest filing, from 7007274.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 7007274.0 in Q4 2025 and bottomed at 46254236.0 in Q3 2023.
- Historically, Income from Continuing Operations has averaged 13632198.18 across 5 years, with a median of 8073146.0 in 2024.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations tumbled 2136.41% — and 2025, when it jumped 149.18%.
- Planet 13 Holdings' Income from Continuing Operations stood at 44012228.0 in 2022, then soared by 67.6% to 14258281.0 in 2023, then increased by 0.07% to 14248508.0 in 2024, then surged by 149.18% to 7007274.0 in 2025, then plunged by 215.53% to 8095802.0 in 2026.
- Business Quant data shows PLNH's Income from Continuing Operations at 8095802.0 in Q1 2026, 7007274.0 in Q4 2025, and 43955853.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 1.33 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Planet 13 Holdings | 52.64 Mn | 36.16 Mn | 12.32 Mn | -5.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -5.59 Mn |
| Mar 31, 2026 | -8.10 Mn |
| Dec 31, 2025 | 7.01 Mn |
| Sep 30, 2025 | -43.96 Mn |
| Jun 30, 2025 | -13.30 Mn |
| Mar 31, 2025 | -2.88 Mn |
| Dec 31, 2024 | -14.25 Mn |
| Sep 30, 2024 | -7.14 Mn |
| Jun 30, 2024 | -8.07 Mn |
| Mar 31, 2024 | -5.89 Mn |
| Dec 31, 2023 | -14.26 Mn |
| Sep 30, 2023 | -46.25 Mn |
| Jun 30, 2023 | -4.66 Mn |
| Mar 31, 2023 | -8.48 Mn |
| Dec 31, 2022 | -44.01 Mn |
| Sep 30, 2022 | -6.34 Mn |
| Jun 30, 2022 | -7.09 Mn |
| Mar 31, 2022 | -4.07 Mn |
| Dec 31, 2021 | -12.46 Mn |
| Sep 30, 2021 | 4.05 Mn |